University of Nebraska Medical Center

Arpan Acharya, PhD

Research Interests

1) Host pathogen interaction

2) Molecular pathogenesis of emerging and reemerging viral outbreaks

3) Characterization and quantification of HIV reservoirs

  • PhD in Biotechnology, Pune, India, 2016

Positions and Scientific Appointments

2024-current: Assistant Professor, Department of Pharmacology and Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska.

2021 - 2024: Instructor, Department of Pharmacology and Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska.

2018 - 2021: Postdoctoral Research Associate, Department of Pharmacology and Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska.

2016 - 2017: Senior Scientist, S N Genelab Pvt. Ltd., Surat, India.

2024 - Associate Editor Frontiers in Virology (Translational Virology)

  • 2023: Young Investigator Award at 40th Annual Symposium on Nonhuman Primate Models for AIDS (NHP) UC Davis, California.
  • 2021: Scholarship to attend the HIV Pathogenesis and Cure - Keystone eSympisa Virtual Meeting June 1-4, 2021.
  • 2021: New Investigator Award at 28th Conference on Retroviruses and Opportunistic Infections 2021, USA.
  • 2020: Postdoctoral Excellence in Research Award (runner-up) at University of Nebraska Medical Center.
  • 2020: Early Career Investigator Travel Award (ECITA) to attend the 26th Annual Meeting of the Society on Neuroimmune Pharmacology (SNIP) in New Delhi, India.
  • 2019: Young Investigator Award at 37th Annual Symposium on Nonhuman Primate Models for AIDS (NHP) San Antonio, Texas.
  • 2019: Silver “U” Award at UNMC Chancellor’s councils in recognition of dedication and commitment to the University of Nebraska Medical Center.
Selected Publications
  1. Acharya A, Surbaugh K, Thurman M, Wickramaratne C, Myers P, Mittal R, Pandey K, Klug E, Stein SJ, Ravnholdt AR, Herrera VL, Rivera DN, Williams P, Santarpia JL, Kaushik A, Dhau JS, Byrareddy SN.Efficient trapping and destruction of SARS-CoV-2 using PECO-assisted Molekule air purifiers in the laboratory and real-world settings. Ecotoxicol Environ Saf. 2023 Oct 1;264:115487. doi: 10.1016/j.ecoenv.2023.115487. Epub 2023 Sep 18. PubMed PMID: 37729804.
  2. Vann KR, Acharya A, Jang SM, Lachance C, Zandian M, Holt TA, Smith AL, Pandey K, Durden DL, El-Gamal D, Côté J, Byrareddy SN, Kutateladze TG.Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection. Structure. 2022 Sep 1;30(9):1224-1232.e5. doi: 10.1016/j.str.2022.05.020. Epub 2022 Jun 17. PubMed PMID: 35716662; PubMed Central PMCID: PMC9212912 (equal contributing first author).
  3. Acharya A, Pathania AS, Pandey K, Thurman M, Vann KR, Kutateladze TG, Challagundala KB, Durden DL, Byrareddy SN. PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. Clin Transl Med. 2022 Apr;12(4):e806. doi: 10.1002/ctm2.806. PubMed PMID: 35390226; PubMed Central PMCID: PMC8989379.
  4. Acharya A, Pandey K, Thurman M, Klug E, Trivedi J, Sharma K, Lorson CL, Singh K, Byrareddy SN. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. J Virol. 2021 Nov 23;95(24):e0143721. doi: 10.1128/JVI.01437-21. Epub 2021 Sep 22. PubMed PMID: 34550770; PubMed Central PMCID: PMC8610590.
  5. Acharya A, Olwenyi OA, Thurman M, Pandey K, Morsey BM, Lamberty B, Ferguson N, Callen S, Fang Q, Buch SJ, Fox HS, Byrareddy SN. Chronic morphine administration differentially modulates viral reservoirs in SIVmac251 infected rhesus macaque model. J Virol. 2021 Mar 1;95(5). doi: 10.1128/JVI.01657-20. Epub 2020 Dec 16. PubMed PMID: 33328304; PubMed Central PMCID: PMC8092838.


Complete List of Published Work is available in in My Bibliography: